Physician profile
Dale E Mohar
NPI 1194721696
$8,907.15
in general payments reported to CMS, 2019-2025
26 companies · $883 in 2025
The $883 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $212 · 2021: $455 · 2022: $617 · 2023: $3,368 · 2024: $3,233 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,950 · Food and Beverage: $2,484 · Education: $49.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,950.00 |
| Food and Beverage | $2,483.89 |
| Education | $49.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $4,950.00 | 2023-2024 | |
| Glaxosmithkline, LLC. | $1,298.77 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $533.97 | 2021-2024 | Dupixent |
| Genzyme Corporation | $355.73 | 2019-2025 | |
| Blueprint Medicines Corporation | $230.62 | 2023-2025 | Ayvakit |
| Astrazeneca Pharmaceuticals LP | $227.04 | 2019-2025 | Fasenra, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $207.11 | 2022-2025 | Cuvitru, Takhzyro, Eohilia |
| Sanofi-Aventis U.S. LLC | $201.74 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $165.68 | 2023-2025 | |
| Amgen INC. | $165.09 | 2021-2025 | Tezspire |
| Alk-Abello, INC | $81.78 | 2020-2022 | |
| Csl Behring | $77.61 | 2022-2024 | Hizentra |
| Kaleo, INC. | $69.77 | 2022-2023 | Auvi-Q |
| Grifols USA, LLC | $48.75 | 2023-2025 | Gamunex-C, Xembify |
| Organon LLC | $47.44 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $47.22 | 2025 | Neffy |
| Abbvie INC. | $41.52 | 2022 | |
| Sunovion Pharmaceuticals INC. | $41.00 | 2019 | |
| Pfizer INC. | $37.97 | 2023-2025 | |
| Genentech USA, INC. | $33.25 | 2022-2024 | Xolair |
| Optinose US, INC. | $28.58 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $16.51 | 2023 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dale Mohar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.